The use of muscarinic agonists against specific types of mAchRs in a mouse model of AD has shown promising results such as decrease in β-amyloid plaque accumulation, decrease in tau hyperphosphorylation and improvement in cholinergic activity and improvement in specific memory-related tasks [20,54]. This evidence concerns the gene MAPT and Alzheimer disease.